The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
Open accessAbstract
Objective: Chemokines such as CCL2/monocyte chemotactic protein 1 (MCP‐1) play a key role in leukocyte migration and are potential targets in the treatment of chronic inflammatory disorders. The objective of this study was to evaluate the effects of human anti–CCL2/MCP‐1 monoclonal antibody (ABN912) treatment in patients with rheumatoid arthritis (RA). Methods: Patients with active RA were enrolled in a randomized, placebo‐controlled, dose‐escalation study of ABN912. Infusions were administered on day 1 and day 15. In the dose‐escalation phase, 4 cohorts of 8 patients each underwent serial arthroscopic biopsy of synovial tissue. Immunohistochemistry and digital image analysis were used to characterize biomarkers in synovial tissue. Laboratory evaluation included pharmacokinetic analysis and immunotypic studies of peripheral blood mononuclear cells. To assess the clinical effects of treatment with ABN912, an additional 21 patients were treated with the highest dose tolerated. Results: The total study population comprised 45 patients: 33 patients received ABN912, and 12 patients received placebo. ABN912 treatment was well tolerated. Unexpectedly, there was a dose‐related increase in ABN912‐complexed total CCL2/MCP‐1 levels in peripheral blood, up to 2,000‐fold. There was no detectable clinical benefit of ABN912 compared with placebo, nor did treatment with the study drug result in a significant change in the levels of biomarkers in synovial tissue and peripheral blood. Conclusion: ABN912 treatment did not result in clinical or immunohistologic improvement and may have been associated with worsening of RA in patients treated with the highest dose. The results might be related to the greatly increased level of total CCL2/MCP‐1 in serum that was observed following treatment with ABN912. This observation may be relevant for a variety of antibody‐based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
McQuibban, G. A., Gong, J.-H., Wong, J. P., Wallace, J. L., Clark-Lewis, I., & Overall, C. M. (2002) · Blood · doi:10.1182/blood.v100.4.1160.h81602001160_1160_1167 · Cited by 611
Haringman, J. J., Gerlag, D. M., Zwinderman, A. H., Smeets, T. J. M., Kraan, M. C., Baeten, D., McInnes, I. B., Bresnihan, B., & Tak, P. P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029751 · Cited by 457
Self-citationMurine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 418
Gong, J.-H., Ratkay, L. G., Waterfield, J. D., & Clark-Lewis, I. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.131 · Cited by 375
Loetscher, P., Seitz, M., Lewis, I. C., Baggiolini, M., & Moser, B. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.13.7926371 · Cited by 323
Self-citationChemokines and their receptors in rheumatoid arthritis: Future targets?
Koch, A. E. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20932 · Cited by 247
Cited by
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes
Panee, J. (2012) · Cytokine · doi:10.1016/j.cyto.2012.06.018 · Cited by 402
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
Overcoming hurdles in developing successful drugs targeting chemokine receptors
Schall, T. J., & Proudfoot, A. E. I. (2011) · Nature Reviews Immunology · doi:10.1038/nri2972 · Cited by 318
Chemokine receptor antagonists: overcoming developmental hurdles
Horuk, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2734 · Cited by 303
Metadata
- Authors
- Haringman, J. J., Gerlag, D. M., Smeets, T. J. M., Baeten, D., van den Bosch, F., Bresnihan, B., Breedveld, F. C., Dinant, H. J., Legay, F., Gram, H., Loetscher, P., Schmouder, R., Woodworth, T., & Tak, P. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-07-25
- Volume
- 54
- Issue
- 8
- Pages
- 2387-2392
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2002584410
- Cited by
- 258
- References
- 16
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.21975
- The paper
- Haringman, J. J., Gerlag, D. M., Smeets, T. J. M., Baeten, D., van den Bosch, F., Bresnihan, B., Breedveld, F. C., Dinant, H. J., Legay, F., Gram, H., Loetscher, P., Schmouder, R., Woodworth, T., & Tak, P. P. (2006). A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.21975
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.